My group focuses on enhancer regulation in kidney disease. The aim is to understand the transcriptional regulation of kidney specific programs in normal homeostasis and in kidney injury and repair with focus on enhancer hierarchies, transcription factor identification / cooperation and in-vivo validation with CRISPR/Cas9 gene or base editing tools. We believe our comprehensive analysis of epigenetic changes after kidney injury in-vivo provides a detailed molecular model and rich resource, and has the potential to identify new targets for therapeutic intervention.